18F-FDG PET/CT for the detection of large vessel vasculitis in patients with polymyalgia rheumatica

Revista Espanola de Medicina Nuclear e Imagen Molecular

Volumn 34, Issue 5, 2015, Pages 275-281

  Lavado Perez C ^a   Martinez Rodriguez I ^a   Martinez Amador N ^a   Banzo, I ^a   Quirce, R ^a   Jimenez Bonilla J ^a   De Arcocha Torres, M ^a   Bravo Ferrer, Z ^a   Jimenez Alonso M ^a   Lopez Defillo J L ^a   Blanco, R ^a   Gonzalez Gay M A ^a   Carril, J M ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

18F FDG PET CT; Aortitis; Giant cell arteritis; Large vessel vasculitis; Polymyalgia rheumatica; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FLUORINE; RADIOPHARMACEUTICAL AGENT;

ABDOMINAL AORTA; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE ASSOCIATION; DRUG UPTAKE; FEMALE; FEMORAL ARTERY; GREAT BLOOD VESSEL; HUMAN; ILIAC ARTERY; MALE; RHEUMATIC POLYMYALGIA; SUPRAAORTIC TRUNK; THORACIC AORTA; TIBIOPERONEAL ARTERY; VASCULITIS; AORTITIS; COMPLICATION; DIAGNOSTIC IMAGING; ERYTHROCYTE SEDIMENTATION RATE; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; TISSUE DISTRIBUTION;

AGED; AORTITIS; BLOOD SEDIMENTATION; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POLYMYALGIA RHEUMATICA; POSITRON EMISSION TOMOGRAPHY COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SINGLE-BLIND METHOD; TISSUE DISTRIBUTION; VASCULITIS;

EID: 84938741108     PISSN: 2253654X     EISSN: 22538070     Source Type: Journal    
DOI: 10.1016/j.remn.2015.05.011     Document Type: Article

References (30)

1. González-Gay M.A., García-Porrua C., Vazquez-Caruncho M., Dababneh A., Hajeer A., Ollier W.E. The spectrum of polymyalgia reumática in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study. J Rheumatol 1999, 26:1326-1332.
2. Blockmans D., Maes A., Stroobants S., Nuyts J., Bormans G., Knockaert D., et al. New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography. Rheumatology 1999, 38:444-447.
3. Blockmans D., Stroobants S., Maes A., Mortelmans L. Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch. Am J Med 2000, 108:246-249.
4. Moosig F., Czech N., Mehl C., Henze E., Zeuner R.A., Kneba M., et al. Correlation between 18-fluorodeoxyglucose accumulation in large vessels and serological markers of inflammation in polymyalgia rheumatica: a quantitative PET study. Ann Rheum Dis 2004, 63:870-873.
5. Bejerano C., Blanco R., González-Vela C., Pérez-Martín I., Martinez-Rodriguez I., Jimenez-Bonilla J., et al. Polymyalgia rheumatica as presenting manifestation of vasculitis involving the lower extremities in a patient with ulcerative colitis. Clin Exp Rheumatol 2012, 30:S110-S113.
6. Evans J.M., O'Fallon W.M., Hunder G.G. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med 1995, 122:502-507.
7. Uddhammar A., Eriksson A.L., Nyström L., Stenling R., Rantapää-Dahlqvist S. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 2002, 29:737-742.
8. Nuenninghoff D.M., Hunder G.G., Christianson T.J., McClelland R.L., Matteson E.L. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheumatol 2003, 48:3522-3531.
9. Salvarani C., Cantini F., Boiardi L., Hunder G.G. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002, 347:261-271.
10. González-Gay M.A. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum 2004, 33:289-293.
11. Salvarani C., Gabriel S.E., O'Fallon W.M., Hunder G.G. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991. Arthritis Rheumatol 1995, 38:369-373.
12. Hunder G.G. Giant cell arteritis and polymyalgia rheumatica. Med Clin N Am 1997, 81:195-219.
13. Cantini F., Niccoli L., Storri L., Nannini C., Olivieri I., Padula A., et al. Are polymyalgia rheumatica and giant cell arteritis the same disease?. Semin Arthritis Rheum 2004, 33:294-301.
14. Gonzalez-Gay M.A., Barros S., Lopez-Diaz M.J., Garcia-Porrua C., Sanchez-Andrade A., Llorca J. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine 2005, 84:269-276.
15. Clifford A., Burrell S., Hanly J.G. Positron emission tomography/computed tomography for the diagnosis and assessment of giant cell arteritis: when to consider it and why. J Rheumatol 2012, 39:1909-1911.
16. Yamada S1, Kubota K., Kubota R., Ido T., Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med 1995, 36:1301-1306.
17. Meller J., Strutz F., Siefker U., Scheel A., Sahlmann C.O., LehmannK., et al. Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. Eur J Nucl Med Mol Imaging 2003, 30:730-736.
18. 18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging 2005, 32:674-681.
19. Blockmans D., De Ceuninck L., Vanderschueren S., Knockaert D., Mortelmans L., Bobbaers H., Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients Rheumatology 2007, 46:672-677.
20. 18F-fludeoxyglucose PET/CT in the evaluation of large-vessel vasculitis: diagnostic performance and correlation with clinical and laboratory parameters. Br J Radiol 2012, 85:e188-e194.
21. Martínez-Rodríguez I., Del Castillo-Matos R., Quirce R., Jiménez-Bonilla J., De Arcocha-Torres M., Ortega-Nava F., et al. Comparison of early (60min) and delayed (180min) acquisition of (18)F-FDG PET/CT in large vessel vasculitis. Rev Esp Med Nucl Imagen Mol 2013, 32:222-226.
22. Riancho J., Infante J., González-Vela C., Carril J.M., Bercian J., Martínez-Rodríguez I. Acute imbalance and constitutional syndrome: the answer may lie on the front of the head. J Rheumatol 2014, 41:143-144.
23. 18F-FDG PET/CT acquisition images. Eur J Nucl Med Mol Imaging 2014, 41:2319-2324.
24. Treglia G1, Mattoli M.V., Leccisotti L., Ferraccioli G., Giordano A. Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review. Clin Rheumatol 2011, 30:1265-1275.
25. 18F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels. Eur J Nucl Med Mol Imaging 2014, 41:369-383.
26. Yamashita H., Kubota K., Takahashi Y., Minaminoto R., Morooka M., Ito K., et al. Whole-body fluorodeoxyglucose positron emission tomography/computed tomography in patients with active polymyalgia rheumatica: evidence for distinctive bursitis and large-vessel vasculitis. Mod Rheumatol 2012, 22:705-711.
27. 18F-FDG PET/CT uptake pattern at 60' (early) and 180' (delayed) acquisition in a control population: visual and semiquantitative comparative analysis. Nucl Med Commun 2013, 34:926-930.
28. Cimmino M.A., Zampogna G., Parodi M. Is FDG-PET useful in the evaluation of steroid-resistant PMR patients. Rheumatology 2008, 47:926-927.
29. 18F-FDG PET on the management of patients with suspected large vessel vasculitis. Eur J Nucl Med Mol Imaging 2012, 39:344-353.
30. 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheumatol 2006, 55:131-137.